Introduction: Primary small cell carcinoma of the esophagus (PSCCE) is characterized by high malignancy, early metastasis, and poor prognosis. This retrospective study aimed to review the clinical characteristics of patients with limited-stage PSCCE and determine the relevant prognostic factors and optimal treatment strategies.
Introduction
Esophageal carcinoma is one of the fastest-growing tumor types worldwide and is estimated to be the third most common cancer in China and the fourth leading cause of cancer death in 2015. 1 The most common histological types are squamous cell carcinoma and adenocarcinoma. Primary small cell carcinoma of the esophagus (PSCCE) is a particularly rare malignancy, accounting for 0.5% to 2.8% of all esophageal malignancies. poor prognosis. The optimal and standard treatment for limited-stage PSCCE has not been established; surgery, chemotherapy (CT), and radiation therapy (RT) have been performed alone or in combination with different treatment outcomes. Moreover, because PSCCE is an especially rare malignancy, evidence supporting these therapeutic strategies is limited to small retrospective series, and future prospective randomized trials are unlikely. In this retrospective study, we reviewed the clinical characteristics of patients with limited-stage PSCCE and evaluated the relevant prognostic factors and optimal treatment strategies in a relatively large cohort with limited-stage PSCCE.
Patients and Methods

Patient Selection and Staging
We retrospectively evaluated 152 consecutive patients with limited-stage PSCCE who underwent treatment at the Affiliated Cancer Hospital of Zhengzhou University (Henan Cancer Hospital) between January 2007 and December 2015. Patients were selected on the basis of the following eligibility criteria: (1) histopathologically proven PSCCE, (2) proven limited-stage disease, and (3) complete medical records. Patients were excluded on the basis of the following criteria: (1) a diagnosis of esophageal carcinoma other than limitedstage small cell carcinoma of the esophagus (SCCE) (e.g., other neuroendocrine carcinoma, squamous cell carcinoma, or adenocarcinoma), (2) uncontrolled comorbid conditions (metabolic or psychiatric), and (3) incomplete medical records.
All patients provided a detailed history and underwent the following procedures: physical examination; laboratory tests; computed tomography scans of the brain, neck, chest, and upper abdomen; barium esophagography; painless esophageal and gastral endoscopic ultrasonography; and emission computed tomography bone scan and/or positron emission tomography of the body. Immunohistochemical staining was performed to determine the direct or indirect presence of common neuroendocrine markers, including synaptophysin (Syn), neuron-specific enolase (NSE), chromogranin A (CgA), cytokeratin 56, cytokeratin (CK), and lymphocyte antigen 56 (CD56). In all the patients PSCCE was pathologically diagnosed by endoscopic biopsy before treatment.
The patients were staged according to the seventh edition of the American Joint Committee on Cancer (AJCC) TNM Classification of Carcinoma of the esophagus and Esophagogastric Junction 10 and Veterans Administration Lung Study Group stage. 11, 12 Regarding the AJCC system, inoperable patients were staged according to the clinical TNM staging system, and patients undergoing resection were adapted to the pathological TNM staging system. This second system comprises two staging categories: limited disease and extensive disease. Limited disease is defined as a tumor confined within a localized anatomic region with or without regional lymph node metastasis.
Treatment Modalities
The subjects selected for the present study included 100 patients who had undergone radical esophagectomy with two-or three-field lymph node dissection and 52 patients who did not receive an operation (20 patients received CRT, four patients received RT, and 28 patients received chemoradiotherapy [CRT] ). Surgical procedures included open transthoracic esophagectomy and minimally invasive esophagectomy (MIE). MIE was defined as an operation performed by both thoracoscopic and laparoscopic techniques. Twelve patients received MIE, and 88 patients received open transthoracic esophagectomy. A total of 34 patients received an operation alone, 34 patients received an operation and adjuvant CT, 12 patients received an operation and adjuvant CRT, four patients received an operation and adjuvant RT, and 16 patients received neoadjuvant CT (nCT) followed by an operation. Of the 152 patients, 107 were treated with two to 10 courses of cisplatin-based CT (e.g., VP-16/ cisplatin, cisplatin/5-FU, and paclitaxel/cisplatin). In all, 48 patients received RT; the target volume covered the primary lesion or the tumor bed with the lymphatic drainage area, and the dose of RT ranged from 40 to 70 Gy. A total of 40 cases were treated with CRT.
Statistical Analyses
Overall survival (OS) was calculated from the start of the treatment to death or the time of last follow-up. Disease-free survival (DFS) was measured as the time from the date of surgery to the date of distant metastasis or local recurrence or the date of death from any cause. Univariate analysis of survival was conducted by using Kaplan-Meier plots, and the log-rank test was used to compare survival differences. A Cox regression analysis was used to identify the independent prognostic factors in multivariate analysis. Statistical significance was indicated by a p value less than 0.05. These analyses were performed with the statistical software package SPSS 17.0 (SPSS Inc., Chicago, IL).
Results
Patient Information and Tumor Characteristics
The characteristics of the cohort and tumors of the 152 patients are listed in Table 1 . The study group comprised 104 men (68.4%) and 48 women (31.6%), with their ages ranging from 34 to 85 years and a mean age of 61. Thirty-nine patients (25.7%) had risky diets or a history of alcohol abuse, and 43 patients (28.3%) had a smoking index greater than 400.
Thirty-six patients (23.7%) had chronic diseases, including diabetes, hypertension, heart disease, and viral hepatitis. Thirty-two patients (21.1%) had a family history of malignancy.
In the present study, the middle third of the thoracic esophagus was the most common location of primary tumors (51.3%). A total of 11.2% of tumors were located in the upper thoracic esophagus, and 37.5% of tumors were located in the lower segment. The lengths of these lesions ranged from 1.0 cm to 11.0 cm). In 11.1% of cases, the tumor size was large (>6 cm), with 75.7% of cases showing tumor sizes larger than 2 cm but no larger than 6 cm and 13.2% showing tumor sizes 2 cm or less. Regarding histological type, 66.4% of the specimens were pure SCCE, whereas 11.7% of the specimens were combined with squamous cell carcinoma, 13.7% were combined with adenocarcinoma, and 8.2% were combined with adenosquamous carcinoma. 
OS
The median follow-up time was 26.5 months (range 1.0-116.0). By December 2015, 11 patients (7.2%) were still living, 130 patients (85.5%) had died, and 11 patients (7.2%) were lost to follow-up. The median survival time (MST) of the 152 patients was 28.0 months (95% confidence interval [CI]: 22.9-33.1), and 
Prognostic Factor Analysis
We evaluated the relationship between patient prognosis and clinicopathological features, such as sex, age, family history of malignancy, combined additional components, length of lesion, location, stage, and treatment modalities (Table 2 ). In the univariate analysis, MST was significantly longer for patients who underwent radical esophagectomy with two-or three-field lymph node dissection compared with those who did not ( However, other clinicopathological features, including sex, age (60 versus >60 years), alcohol abuse, smoking index (400 versus >400), other chronic disease, family history of malignancy, macroscopic tumor type, and combined additional components, did not show significant correlations with prognosis (p > 0.05).
According to multivariate analysis, treatment modality (relative risk ¼ 0.661, 95% CI: 0.451-0.970, p ¼ 0.034) and N stage (relative risk ¼ 1.395, 95% CI: 1.135-1.713, p ¼ 0.002) were independent prognostic factors ( Table 3) .
Treatment and Survival
Finally, we further studied the impact of treatment strategies on the survival of patients with PSCCE in a stratified analysis. Subgroup analysis was performed on the basis of TNM stage and by treatment strategy (Table 4) . Among the 152 patients, the patients who received an operation alone exhibited an MST of 39.0 months, and the 1-, 3-, and 5-year OS rates were 91.2%, 50.4%, and 10.1%, respectively. For patients who received nonsurgical therapies, the MST was 17.0 months, and the 1-, 3-, and 5-year OS rates were 72.5%, 20.3%, and 4.5%, respectively. Patients who underwent an operation alone exhibited better survival than those who underwent nonsurgical therapies (p ¼ 0.032, Fig. 2B ). Of the 35 patients in the subset with stage I or IIA PSCCE, those who underwent nonsurgical therapies exhibited an MST of 25.0 months and their 1-, 3-, and 5-year OS rates were 100.0%, 33.3%, and 0%, respectively. For patients who received an operation alone, the MST was 43.0 months and the 1-, 3-, and 5-year OS rates were 100.0%, 100.0%, and 37.5%, respectively. For patients who received an operation plus postoperative adjuvant therapy, the MST was 36.0 months and the 1-, 3-, and 5-year OS rates were 80.0%, 50.0%, and 15.0%, respectively. Patients who underwent an operation alone had a better survival than those who underwent nonsurgical therapies, but the OS rates of patients who underwent an operation plus postoperative adjuvant therapy were similar to those of patients who underwent an operation alone (p ¼ 0.031 and p ¼ 0.522, respectively) (Fig. 2C) .
The patients who received an operation alone showed a median DFS (mDFS) of 52.0 months, and their 1-, 3-, and 5-year DFS rates were 100.0%, 66.7%, and 33.3%, respectively; for the patients who received an operation plus postoperative adjuvant therapy, the mDFS was 26.0 months and the 1-, 3-, and 5-year DFS rates were 70.0%, 40.0%, and 15.0%, respectively. The DFS rates of patients who underwent an operation plus postoperative adjuvant therapy were similar to those of patients who underwent an operation alone (p ¼ 0.368) (Fig. 2D) . Among the 39 patients in the subset of patients with IIB PSCCE, patients who underwent nonsurgical therapies exhibited an MST of 31.0 months and their 1-, 3-, and 5-year OS rates were 83.3%, 16.7%, and 16.7%, respectively. For patients who received an operation alone, the MST was 32.0 months and the 1-, 3-, and 5-year OS rates were 100.0%, 38.5%, and 0%, respectively. For patients who received an operation plus postoperative adjuvant therapy, the MST was 29.0 months and the 1-, 3-, and 5-year OS rates were 80.0%, 40.0%, and 13.3%, respectively. The OS rates of patients who underwent an operation with or without postoperative adjuvant therapy were similar to those of patients who underwent nonsurgical therapies (p ¼ 0.719 and p ¼ 0.603) (Fig. 3A) . The patients who received an operation alone showed an mDFS of 32.0 months and 1-, 3-, and 5-year DFS rates of 80.0%, 23.3%, and 0%, respectively. For those patients who received an operation plus postoperative adjuvant therapy, the mDFS was 26.0 months and the 1-, 3-, and 5-year DFS rates were 66.7%, 33.3%, and 13.3%, respectively. The DFS rates of patients who underwent an operation plus postoperative adjuvant therapy were similar to those of patients who underwent an operation alone (p ¼ 0.412) (Fig. 3B) .
Among the 75 patients in the subset of patients with stage III PSCCE, those who received nonsurgical therapies showed an MST of 15.0 months and 1-, 3-, and 5-year OS rates of 66.7%, 15.4%, and 2.6%, respectively. For patients who received an operation alone, the MST was 23.0 months and the 1-, 3-, and 5-year OS rates were 80.0%, 20.0%, and 0%, respectively. For patients who received an operation plus postoperative adjuvant therapy, the MST was 22.0 months and the 1-, 3-, and 5-year OS rates were 73.3%, 13.3%, and 6.7%, respectively. For patients who received nCT, the MST was 43.0 months and the 1-, 3-, and 5-year OS rates were 100.0%, 50.0%, and 0%, respectively. The OS rates of patients who underwent an operation with or without postoperative adjuvant therapy were similar to those of patients who underwent nonsurgical therapies (p ¼ 0.569 and p ¼ 0.242, respectively) (Fig. 3C ). The OS rates of patients who underwent nCT were better than those of patients who underwent an operation or nonsurgical therapies (p ¼ 0.021 and p ¼ 0.026, respectively (see Fig. 3C ). Those patients who received an operation alone showed an mDFS of 23.0 months and 1-, 3-, and 5-year DFS rates of 60.0%, 20.0%, and 0%, respectively. For the patients who received an operation plus postoperative adjuvant therapy, the mDFS was 17.0 months and the 1-, 3-, and 5-year DFS rates were 60.0%, 6.7%, and 6.7%, respectively. For patients who received nCT, the mDFS was 43.0 months and the 1-, 3-, and 5-year DFS rates were 63.6%, 45.5%, and 0%, respectively. The DFS rates of patients who underwent nCT were better than those of patients who underwent an operation alone, but the DFS rates of patients who underwent an operation plus postoperative adjuvant therapy were similar to those of patients who underwent an operation alone (p ¼ 0.031 and p ¼ 0.494, respectively) (Fig. 3D) .
Discussion
Esophageal carcinoma is one of the fastest-growing tumor types in the world. PSCCE is a particularly rare malignancy, accounting for 0.5% to 2.8% of all esophageal malignancies. [2] [3] [4] [5] [6] [7] [8] In recent years, PSCCE has attracted increasing attention, with rising numbers of reports on PSCCE. The epidemiological manifestations of PSCCE are similar to those of other esophageal malignancies. The results show that PSCCE occurs in the elderly and in men more than in women, and that this tumor develops mostly in the middle and lower thoracic esophagus; macroscopic medullary and ulcerative tumor types are relatively common. These results are similar to those reported previously. 7, 13, 14 On the basis of macroscopic tumor type and imaging, it is difficult to distinguish SCCE from adenocarcinoma and squamous cell carcinoma. A diagnosis of SCCE ultimately depends on histopathological examination and immunohistochemistry (IHC) to improve the accuracy of diagnosis. Esophagoscopic biopsy is the most frequently used method for preoperative diagnosis. Most scholars 7, 15, 16 support the idea that SCCE arises from pluripotent stem cells of the endoderm, which differentiate into adenocarcinoma, squamous cell carcinoma, or SCC. The coexistence of SCCE with squamous cell carcinoma and/or adenocarcinoma in the same carcinoma is evidence for this viewpoint. The reported incidence rate of combined additional components ranges from 9.4% to 38.4%. 7, 17, 18 In the present study, SCCE combined with squamous cell carcinoma and/or adenocarcinoma was observed in 33.6% of patients. The 2015 WHO Classification of Tumors of the Lung advocated that small cell carcinoma and complex atypical carcinoid and other neuroendocrine tumors be classified as lung neuroendocrine carcinoma. 19 SCCE is sometimes distinguished from other neuroendocrine carcinomas, poorly differentiated squamous cell carcinoma, or adenocarcinoma by using IHC. Beasley 20 reported that IHC evaluation of neuroendocrine markers such as Syn, CgA, NSE, CK, CD56, and SCLC is diagnostically helpful. In the present study, the positive rates for Syn, CgA, NSE, CK, CD56, and SCLC were 97.9%, 45.8%, 90.0%, 75.0%, 86.6%, and 81.0%, respectively. In addition, the Ki-67 labeling index is one of the defining features of SCLC, differentiating this disease from typical and atypical carcinoids. 19 It is generally believed that the Ki-67 labeling index is higher than 50% (average 80%) in small cell carcinoma and most atypical carcinoids have a proliferation index less than 25%. 19, [21] [22] [23] In the present study, the median Ki-67 labeling index was 80% (range 50%-95%).
PSCCE is characterized by rapid progression and aggressive invasion. Regional lymph node metastasis typically develops early. A previous study 24 showed that regional lymph node metastasis developed in 65.1% of patients (84 of 129). Zhu et al. 7 reported that the rate of lymph node metastasis was 79.0%. In the present study, regional lymph node metastasis developed in 65.8% of patients (100 of 152). Univariate analysis and Cox regression analysis showed that N stage was an independent prognostic factor. The MST of patients with N0 disease was longer than that of patients with N1, N2, or N3 disease (39.0 versus 28.0 versus 20.0 versus 14.0 months, respectively [p < 0.001]). Zhang et al. 25 recently reported that lymph node involvement was an independent prognostic factor for patients with limited-stage SCCE. Sun et al. 26 showed that the OS of patients without lymph node metastases was longer than that of patients with lymph node metastases. Situ et al. 27 reported that the presence of multiple regional lymph nodes metastases was associated with a poorer prognosis. These data support the viewpoint that N stage is an independent prognostic factor of limited-stage PSCCE.
PSCCE is characterized by high malignancy and poor prognosis. Because PSCCE is a particularly rare malignancy, evidence supporting these therapeutic strategies is limited to small retrospective series. Therefore, the optimal and standard treatment for limited-stage PSCCE has not been established. There is controversy over whether surgery is helpful in prolonging the survival of patients with PSCCE. [27] [28] [29] [30] [31] In a systematic analysis of 225 patients with limited-stage PSCCE, Gao et al. 32 showed a significant difference in MST between the CT and non-CT groups (20 versus 10 months). Meng et al. 31 showed that RT plus CT should be considered as a primary approach for these patients with PSCCE. However, Kukar et al. 33 demonstrated that surgery could effectively extend the OS of patients with limited-stage PSCCE. Xie et al. 34 confirmed that radical operation is an independent prognostic factor. Surgical treatment plays an important role in the treatment of limited-stage SCCE. In the present study, the MST of the patients treated with surgery was longer than that of those who received nonsurgical therapies (32.0 months versus 17.0 months [p ¼ 0.003]), and patients who underwent an operation alone had a better survival than those who received nonsurgical therapies (5-year OS rates of 10.1% versus 4.5% [p ¼ 0.032]). However, because of stage bias, OS analyses by treatment modality are questionable. In the present study, the primary treatments for patients with different stages are different (Table 4) . Therefore, the subgroup analysis should be performed on the basis of TNM stage grouping and treatment strategy. Wong et al. 35 confirmed that esophagectomy (MST of 44.9 months and 3-year OS of 50.5%) was associated with the best OS for patients with localized (node-negative) disease compared with CT alone (p < 0.001) or CRT (p ¼ 0.01).
Sun et al. 26 retrospectively analyzed the clinical data of 73 patients with PSCCE who had been treated with surgery and advocated that surgery be considered the leading method for patients with stage I or II PSCCE. In the present study, patients who underwent an operation alone exhibited better survival than those who underwent nonsurgical therapies, but compared with surgery alone, postoperative adjuvant therapy could not improve OS and DFS. This result is consistent with the findings of Chen et al. 23 and Zou et al. 12 Chen et al. 23 reported that surgical procedures alone could improve survival of patients with stage I or IIA PSCCE (MST of 29 versus 17.4 months [p ¼ 0.082]) but CT did not further improve OS. Zou et al. 12 confirmed that adjuvant treatment with postoperative CT alone or postoperative CRT did not increase survival in completely resected disease without nodal involvement. In summary, radical esophagectomy should be considered as the primary treatment for patients with stage I or IIA PSCCE.
For patients with stage IIB PSCCE, the OS rates of patients who underwent an operation were similar to those of patients who underwent nonsurgical treatments and postoperative adjuvant therapy did not increase OS and DFS. Chen et al. 23 reported that RT combined with CT should be the main treatment approach in stage IIB or higher disease and surgery did not further improve OS in these patients. In our study, the patients who underwent nonsurgical treatment included four patients who received CRT and two who received CT. We could not evaluate the difference in survival between patients who underwent an operation and patients who received CRT because of the limited number of patients who underwent nonsurgical treatment. In addition, unmeasured confounders, such as the regimens of CT, the cycles of CT, performance status, and economic conditions of those in the CT group, may have influenced the survival outcomes of the present study. Given the similar survival rates from treatment with the three existing regimens, newer therapeutic approaches are necessary for patients with stage IIB PSCCE. In the present study, there were two patients who underwent nCT (survival time of 55 months and 29 months). However, we could not evaluate whether nCT could improve survival in these patients. Therefore, additional studies are needed to confirm the role of nCT in the management of stage IIB PSCCE.
For patients with stage III PSCCE, a retrospective study 26 of 73 cases of PSCCE recommended that CT and RT be offered to patients with stage III or IV PSCCE. In the present study, the OS rates of patients who underwent an operation with or without postoperative adjuvant therapy were similar to those of patients who underwent nonsurgical therapies (p ¼ 0.569 and p ¼ 0.242, respectively). This result is consistent with the findings of Chen et al. 23 In a retrospective analysis, these authors found that in patients with stage IIB or III PSCCE, surgical treatment did not further improve survival. Finally, we conducted further information analyses of the patients who underwent nCT. We observed that the OS rates of patients who underwent nCT were better than those of patients who underwent an operation alone or nonsurgical therapies (p ¼ 0.021 and p ¼ 0.026) and the DFS rates of patients who underwent nCT were better than those of patients who underwent an operation alone (p ¼ 0.031). Several recent studies [36] [37] [38] [39] [40] have confirmed that nCT is advantageous on the standpoint of the following three aspects: achieving tumor regression grade, increasing complete resection rates, and maximizing the survival benefit of radical esophagectomy. To our knowledge, however, few patients with PSCCE reported underwent neoadjuvant therapy. Tobari et al. 41 reviewed the literature and reported that patients with PSCCE treated with surgery after CT and/or RT had survived longer than those treated with CT and/ or RT. Akiyama et al. 37 reported a patient with PSCCE (cT3N1N0 stage IIIA) achieving a pathologically complete response with nCT. The patient is alive and has a DFS time of 48 months after surgery. These authors concluded that nCT followed by esophagectomy could be an effective treatment option for limited-stage PSCCE. However, as the number of subjects is small and the regimens and cycles of nCT are inconsistent, the merits of nCT need to be further explored.
Conclusion
PSCCE is characterized by high malignancy, early metastasis, and poor prognosis. Treatment modalities and N stage were independent prognostic factors. Although no consensus optimal treatment strategy has been established, the present study suggests that radical esophagectomy be considered as the primary treatment for patients with stage I or IIA PSCCE and that nCT followed by esophagectomy could be an effective treatment option for stage III PSCCE. Surgery with or without postoperative adjuvant therapy did not further improve survival of patients with stage IIB PSCCE. A large cohort and multicenter study and further basic research are required to confirm the role of nCT in the management of limited-stage PSCCE.
